Drug Approval | August 30, 2024
Natco Pharma announces submission of TABRECTA to USFDA
TABRECTA is the brand of Novartis. Natco believes it is the first company to have filed a substantially-complete ANDA
TABRECTA is the brand of Novartis. Natco believes it is the first company to have filed a substantially-complete ANDA
The study highlighted substantial improvements in key clinical parameters among RA patients who underwent AWS intervention
Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
First-in-human Phase-1 study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SUVN-I6107 in healthy subjects
First patient enrolled in the Phase III SOHO-02 trial of investigational agent BAY 2927088 in treatment-naïve patients with advanced NSCLC with HER2-activating mutations
Critical resources will help Genvor to grow and scale biological crop protection products and innovative trait technologies
The partnership will provide health plans with an out-of-the-box compliance solution for CMS-9115 and CMS-0057 rules
Brimonidine Tartrate Ophthalmic Solution, 0.1% is an alpha adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure
The low-profile, 2” Disc Top Lite closure offers lighter weight combined with premium customization options
Launches Opentop 40, Opentop D, Opentop L, Opentop Dsr and Cefix 200 which are available for sale
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
